Drug Profile
Research programme: langerhans cell histiocytosis - Crucell/Johns Hopkins
Alternative Names: Langerhans cell histiocytosis research programme - Crucell/Johns HopkinsLatest Information Update: 27 Jan 2005
Price :
$50
*
At a glance
- Originator Crucell
- Developer Crucell; Johns Hopkins University
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Histiocytosis
Most Recent Events
- 27 Jan 2005 Discontinued - Preclinical for Histiocytosis in Netherlands (unspecified route)
- 27 Jan 2005 Discontinued - Preclinical for Histiocytosis in USA (unspecified route)
- 27 Sep 2002 Preclinical trials in Histiocytosis in Netherlands (unspecified route)